Cancer drug targets BRCA mutations beyond breast and ovarian
NCT ID NCT02286687
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug talazoparib in 150 people with advanced cancers that have not responded to standard treatments. Participants must have specific gene changes in BRCA1, BRCA2, or related DNA repair genes. The drug works by blocking an enzyme that helps cancer cells survive, potentially shrinking tumors or slowing the disease. The study focuses on cancers other than breast or ovarian.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- talazoparib (a PARP inhibitor pill)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced cancers that have specific BRCA or related gene changes, potentially shrinking tumors or delaying progression.
- What could go wrong
- This is a mid-stage trial with only 150 participants, so results may not apply to everyone. Talazoparib can cause side effects like fatigue, nausea, and low blood counts, and the cancer may still grow despite treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart shield for young cancer survivors: new study tests dexrazoxane
- Cancer drug niraparib tested before prostate surgery – early trial stopped
- New antibody drug aims to turn immune cells against cancer
- One-Shot radiation may ease cancer pain as well as multiple sessions
- Experimental cancer drug AUR106 tested in humans for first time
- Keytruda takes on genetic weak spots in advanced tumors